Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Active, not recruiting

• Conditions: Prostatic Neoplasms, Castration-Resistant

• Registration Number: NCT04962919
• Lead Sponsor: Latin American Cooperative Oncology Group

Brief Summary

Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-14
• Study First Submitted: 2021-06-24
• Study First Submitted QC: 2021-07-06
• Study First Posted: 2021-07-15
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-10
• Last Update Posted: 2025-02-11
• Primary Completion: 2025-05-07
• Study Completion: 2025-05-07

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 584

Inclusion Criteria

• Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Exclusion Criteria

• Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
• Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.	December of 2017

Secondary Outcome Measures

Name	Time	Method
To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;	December of 2017
To describe the presence or absence of treatments bone-directed	December of 2017
To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;	December of 2017
To describe the rates of skeletal-related complications	December of 2017
To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;	December of 2017
To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;	December of 2017
To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;	December of 2017
To describe the rate of admissions	December of 2017
To describe the number of lines of treatment that patients have undergone	December of 2017

Trial Locations

Locations (8)

Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO; 🇧🇷 Santo André, São Paulo, Brazil

Sírio Libanês; 🇧🇷 São Paulo, SP, Brazil

CPO Pucrs; 🇧🇷 Porto Alegre, RS, Brazil

A.C.Camargo Cancer Center; 🇧🇷 São Paulo, Brazil

Centro Paulista de Oncologia; 🇧🇷 São Paulo, SP, Brazil

BP - A Beneficência Portuguesa de São Paulo; 🇧🇷 São Paulo, Brazil

Hospital Santa Marcelina; 🇧🇷 São Paulo, Brazil

Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central; 🇧🇷 São Paulo, Brazil